The common pattern of cytokeratin alteration in alcoholic and cholestatic liver disease is different from that of hepatitic liver damage. A study with the panepithelial monoclonal antibody lu-5.
The patterns of cytokeratin as determined by murine monoclonal antikeratin antibody lu-5 (mAb lu-5) were quantitated in paraffin-embedded liver tissue from normal and diseased subjects. In tissue from healthy medical students, mAb lu-5 was found to decorate 2-4 periportal and 2-3 perivenular cell layers. Alcoholic liver disease was accompanied by a marked increase in intensity of mAb lu-5 antigen expression in zone I and III hepatocytes. Moreover, additional liver cells of both zones were progressively recruited, so that in advanced lesions all three lobular zones became positive. In mechanical as well as in drug-induced cholestasis, a similar increase of mAb lu-5 antigen expression was already observed in earlier stages of disease, including an earlier recruitment of zone II hepatocytes. In both alcoholic and cholestatic biopsies the intensity and extent of mAb lu-5 epitope expression increased with the duration and severity of disease. In primary biliary cirrhosis (PBC) and seemingly also in primary sclerosing cholangitis the increase and extent was more marked in zone I, the zone of assumed cholate accumulation. Changes in zone III, the territory of histologic cholestasis (bilirubinostasis), became evident only in late stages of PBC. Mallory bodies of alcoholic and cholestatic liver disease showed an identical mAB lu-5 antigen expression, thus giving rise to four different staining patterns. Changes of cytokeratin expression are similar in alcoholic and cholestatic liver diseases. In chronic viral hepatitis, however, cytokeratin alterations are discrete and restricted to precirrhotic/cirrhotic stages.
Müllhaupt
B
B
Department of Pathology, University of Basel, Switzerland.
Gudat
F
F
Epper
R
R
Bianchi
L
L
D000911:Antibodies, Monoclonal; D001706:Biopsy; D002779:Cholestasis / Q000378:metabolism* / Q000473:pathology; D002908:Chronic Disease; D004848:Epithelium / Q000276:immunology; D006525:Hepatitis, Viral, Human / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007633:Keratins / Q000032:analysis*; D008108:Liver Diseases, Alcoholic / Q000378:metabolism* / Q000473:pathology; D016612:Paraffin Embedding; D015203:Reproducibility of Results; D012189:Retrospective Studies
D000911:Antibodies, Monoclonal; D007633:Keratins